HS-IT101

Phase 1Biologic

TThe Affiliated Hospital of Qingdao University

HS-IT101 is one of 117 biologic programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerNot yet recruiting

Advanced Solid TumorsRecruiting

Advanced Solid TumorNot yet recruiting

Breast CancerPhase 1

Not yet recruiting

Advanced Solid TumorsPhase 1

Recruiting

Advanced Solid TumorPhase 1

Not yet recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Zolymbus

AbbVie

Preclinical

1 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

Spravato

WWim Janssens

Preclinical

2 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Acupan

YYonsei University

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Advanced Solid Tumor

NCT05539768

Phase 1Not yet recruiting

Breast Cancer

NCT05505812

Q1 2028

Phase 1Recruiting

Advanced Solid Tumors

NCT06342336

Clinical

Trials by Indication[1]

Advanced Solid Tumor1 trial

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor

Not yet recruiting·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT05539768·8 enrolled

Advanced Solid Tumors1 trial

HS-IT101 Injection in the Treatment of Advanced Solid Tumors

Recruiting·QQingdao Sino-Cell Biomedicine Co., Ltd.·Phase 1·NCT06342336·44 enrolled

Breast Cancer1 trial

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer

Not yet recruiting·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT05505812·10 enrolled

Advanced Melanoma1 trial

Single Arm, Phase I Clinical Study of HS-IT101 Injection in the Treatment of Advanced Melanoma

Completed·QQingdao Sino-Cell Biomedicine Co., Ltd.·Phase 1·NCT06941818·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for HS-IT101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HS-IT101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HS-IT101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Hospital of Qingdao University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TThe Affiliated Hospital of Qingdao University

HS-IT101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Trials by Indication[1]

Advanced Solid Tumor1 trial

Advanced Solid Tumors1 trial

Breast Cancer1 trial

Advanced Melanoma1 trial

References

Drug Info

Quick Facts

Related News